= Discovery stage. |
= Translation stage. |
= Clinically available. |
Topic: Troubleshooting
Authors: Koen van der Drift, Jacqueline Hubbard
|
||
Short Abstract Problem: During development of a method to quantify opioids via LC-MSMS in urine, we noticed that the highest two calibrators in our standard curve exhibited a downward skew, regardless of concentration. The deviation appears in components with both low and high concentration ranges, and not all components follow the same trend. Method Information: • LC-MSMS of 19 opioids plus matched deuterated internal standards • Standard curve was prepped in drug free urine o Lowest range: 0.2 – 200 ng/mL o Highest range: 10 – 10000 ng/mL • Internal standard mixture was prepared in MeOH • Sample prep: o Samples were processed using either: Dilute and Shoot (D&S; 1:10 in water) Solid Phase Extraction (Waters Oasis MCX PRiME SPE) Dual Mode Extraction (Biotage DME+) o C18 UPLC BEH 2.1x100 mm, 1.7 m o 8 min gradient @ 30 °C, 0.4 mL/min, 10 L inj o Mobile phase A: water/0.1% FA; mobile phase B: ACN/0.1% FA o Waters Acquity TQD in MRM mode, 2 transitions per component, 1 for IS Troubleshooting Steps: • Observation was independent of standard curve preparation o Serial or parallel dilutions o Logarithmic or evenly spaced calibrators o Some components are not affected -> suggests curve is prepared properly • Appears to be more prominent on plate-based sample preps, suggesting sample loss at higher concentrations, maybe due to adsorption to sample handling surfaces • Less with D&S which is prepped in glass autosampler vials • Area counts of each compound and the internal standard were monitored Outcome: Response at higher concentrations for some components is suppressed in MS. Limit range to 2 logs: • Lowest range: 1-100 ng/mL • Highest range: 20-2000 ng/mL • Glass vials vs plate was red herring; D&S is less concentrated, so less suppression.
|
||
Long Abstract Problem Method Information Troubleshooting Steps Outcome |
||
References & Acknowledgements:
|
Description | Y/N | Source |
Grants | no | |
Salary | no | |
Board Member | no | |
Stock | no | |
Expenses | no |
IP Royalty: no
Planning to mention or discuss specific products or technology of the company(ies) listed above: | no |